Briefing
A Randomized Trial of Maintenance Systemic Therapy After Radiation for Oligometastatic Renal Cell Carcinoma (ASTROs)
Recruiting MD Anderson phase 2 randomized trial (org study ID 2023-0006) of 1 year of pembrolizumab versus observation after definitive radiation for oligometastatic RCC. ClinicalTrials.gov API v2 on 13 Nov 2026: RECRUITING, estimated enrollment 144, start 2023-10-31, primary completion 2029-01-01. Chad Tang, MD, is principal investigator and central contact. Exploratory objectives include association of peripheral-blood and tissue markers with outcomes; the protocol text does not name K-COMPASS. The ASCO GU 2026 K-COMPASS abstract states that external validation is planned but does not identify ASTROs.
- Design: Phase 2 · Recruiting